Skip to main content
Premium Trial:

Request an Annual Quote

Tekmira Inks Target Validation, Data-Sharing Deal with Bristol-Myers Squibb


Tekmira Pharmaceuticals said this week that it has signed a four-year target-validation deal with drug maker Bristol-Myers Squibb.

Under the deal, Bristol-Myers Squibb will use siRNAs formulated with Tekmira's stable nucleic acid-lipid particle-based delivery technology to "validate the function of certain cellular targets," the companies said.

Notably, Bristol-Myers Squibb will conduct the preclinical validation work, but has agreed to share the data it generates with Tekmira, which is free to use the data to develop RNAi-based drugs against the targets.

Tekmira will receive $3 million upfront, and is responsible for providing "a pre-determined number of the SNALP batches over the four-year agreement," the firms said. "Bristol-Myers Squibb will have a first right to negotiate a licensing agreement on certain RNAi products developed by Tekmira that evolve from gene targets" it validates.

Additional terms were not disclosed.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more